AskAt Inc. (AskAt) (Headquarters: Nagoya, Japan, CEO: Akihiro Furuta) announced today that Arrys Therapeutics, Inc. (Headquarters: Cambridge, Massachusetts), which licensed AAT-007 in immuno-oncology from AskAt in December 2017, has initiated a clinical study with AAT-007 (grapiprant) (ARY-007) in combination with pembrolizumab (anti PD-1 antibody, KEYTRUDA®).
The study is an Open-label, Single-arm, Phase 1b clinical trial to evaluate the safety and efficacy of grapiprant in combination with pembrolizumab in patients with advanced or progressive Microsatellite Stable (MSS) Colorectal Cancer (CRC).
Arrys is the sponsor of the study, in collaboration with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
AskAt Inc. (askat-inc.com) is an open collaboration catalyst, built to accelerate innovation in small molecule R&D. AskAt’s highly experienced team designs optimized platforms for life-cycle partnering opportunities in areas of unmet patient needs, including cancer, Alzheimer’s Disease, pain, autoimmune disorders, and blindness caused by macular degeneration.
Arrys Therapeutics, Inc. (www.arrystherapeutics.com) was established by investments from U.S.-based investors OrbiMed and Atlas Venture.
OrbiMed (www.orbimed.com) is a leading investment firm dedicated exclusively to the healthcare sector, with over $14 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies.
About Atlas Venture.
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, Atlas Venture has been building breakthrough biotech startups since 1993. For more information, please visit www.atlasventure.com.